Core Viewpoint - A class action lawsuit has been filed against Maravai LifeSciences Holdings, Inc. for alleged violations of securities laws, specifically related to false and misleading statements made by the company during the class period from August 7, 2024, to February 24, 2025 [1][2][4] Summary by Sections Lawsuit Details - The Schall Law Firm is representing investors in a class action lawsuit against Maravai LifeSciences Holdings, Inc. for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 [1] - Investors who purchased securities during the specified class period are encouraged to contact the firm before May 5, 2025, to participate in the lawsuit [2] Allegations Against the Company - The complaint alleges that Maravai made false and misleading statements to the market, failed to maintain adequate internal controls over financial reporting, improperly recognized revenue from certain transactions in fiscal 2024, and overstated its goodwill [4] - As a result of these actions, the company's public statements were deemed false and materially misleading throughout the class period, leading to investor damages when the truth was revealed [4]

SAN DIEGO, March 04, 2025 (GLOBE NEWSWIRE) -- Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI) securities between August 7, 2024 and February 24, 2025, inclusive (the “Class Period”), have until May 5, 2025 to seek appointment as lead plaintiff of the Maravai class action lawsuit. Captioned Nelson v. Maravai LifeSciences Holdings, Inc., No. 25-cv-00499 (S.D. Cal.), the Maravai class action lawsuit charges Maravai and certain of Mar ...

BOSTON, March 04, 2025 (GLOBE NEWSWIRE) -- Block & Leviton announces that a securities fraud lawsuit has been filed against Maravai LifeSciences Holdings, Inc. (Nasdaq: MRVI) and certain of its executives. Investors who have lost money in their Maravai LifeSciences Holdings, Inc. investment should contact the firm to learn more about how they might recover those losses. For more details, visit https://blockleviton.com/cases/mrvi. What is this all about? On February 25, 2025, before the market opened, Marava ...

Core Viewpoint - Maravai LifeSciences Holdings, Inc is under investigation for potential securities fraud and unlawful business practices following a delay in its earnings release for Q4 and full year 2024, which led to a significant drop in its stock price [1][2]. Group 1: Company Overview - Maravai LifeSciences Holdings, Inc is publicly traded on NASDAQ under the ticker MRVI [1]. - The company announced a delay in its fourth quarter and full year 2024 earnings release on February 25, 2025, citing the need for additional time to complete its year-end financial close process [2]. Group 2: Stock Performance - Following the announcement of the earnings delay, Maravai's stock price fell by $0.87 per share, representing a decline of 21.7%, closing at $3.14 per share on February 25, 2025 [2]. Group 3: Legal Context - Pomerantz LLP is investigating claims on behalf of investors regarding potential securities fraud or other unlawful business practices by Maravai and its officers and/or directors [1]. - Pomerantz LLP is recognized for its expertise in corporate, securities, and antitrust class litigation, having a long history of fighting for the rights of victims of securities fraud [3].

Core Insights - Robbins Geller Rudman & Dowd LLP is investigating potential violations of U.S. federal securities laws involving Maravai LifeSciences Holdings, Inc. This investigation focuses on whether the company and its executives made false or misleading statements or failed to disclose material information to investors [1][2] Company Overview - Maravai LifeSciences Holdings, Inc. is a provider of biologics that support clinical research [2] Recent Developments - On February 25, 2025, Maravai announced a delay in its earnings release and call, which was originally scheduled for the same day, due to the need for additional time to complete its financial close process. Following this announcement, Maravai's stock price fell nearly 22% [3]

SAN FRANCISCO, Feb. 28, 2025 /PRNewswire/ -- On February 25, 2025, the share price of Maravai LifeSciences (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, plummeted 21% after the company announced it is delaying its Q4 and FY 2024 earnings release and said it requires additional time to complete its year-end financial close process.Hagens Berman is investigating possible accounting misconduct and urges investors who purchased Maravai LifeScience ...

NEW YORK, Feb. 26, 2025 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP is investigating potential claims against Maravai Lifesciences Holdings, Inc. ("Maravai" or the "Company") (NASDAQ:MRVI). The investigation concerns whether Maravai and/or certain of its officers have violated the federal securities laws and/or engaged in other unlawful business practices. [LEARN MORE ABOUT THE INVESTIGATION] On February 25, 2025, Maravai postponed its Q4 and FY24 earnings release and delayed filing its Form 10 ...

BOSTON, Feb. 25, 2025 (GLOBE NEWSWIRE) -- Block & Leviton is investigating Maravai Lifesciences Holdings, Inc (NASDAQ:MRVI) for potential securities law violations. Investors who have lost money in their Maravai Lifesciences Holdings, Inc investment should contact the firm to learn more about how they might recover those losses. For more details, visit https://blockleviton.com/cases/mrvi. What is this all about? Shares of Maravai LifeSciences Holdings fell over 14% in pre-market trading on the morning of Fe ...

Core Viewpoint - Maravai LifeSciences Holdings, Inc. is postponing its earnings release and call originally scheduled for February 25, 2025, and will file a Notification of Late Filing with the SEC due to delays in completing its year-end financial close process [1][2] Financial Reporting Delays - The company requires additional time to assess a potential non-cash impairment charge related to goodwill from its acquisition of Alphazyme LLC [2] - An error in revenue recognition was identified, where approximately $3.9 million in revenue was incorrectly recorded, but this is not expected to impact the full-year 2024 revenue, which is anticipated to be between $255 million and $265 million [2] - Maravai is also assessing the effectiveness of its disclosure controls and internal controls over financial reporting as of December 31, 2024, including remediation of a material weakness in internal controls over revenue recognition [2] Company Overview - Maravai is a leading life sciences company that provides essential products for drug therapies, diagnostics, and vaccine development, serving major biopharmaceutical, vaccine, diagnostics, and cell and gene therapy companies [3]

Core Viewpoint - Maravai LifeSciences Holdings, Inc. expects to report total revenue for 2024 near the mid-point of the previously announced guidance range of $255.0 million to $265.0 million, based on preliminary year-end results [1][4]. Financial Results Announcement - The company plans to announce its fourth quarter and full year 2024 financial and operating results after the market closes on February 25, 2025, and will host a conference call and webcast at 2:00 p.m. PT/5:00 p.m. ET on the same day [2]. Company Overview - Maravai is a leading life sciences company that provides critical products for the development of drug therapies, diagnostics, and novel vaccines, supporting research on human diseases. The company specializes in nucleic acid synthesis and biologics safety testing for biopharmaceutical, vaccine, diagnostics, and cell and gene therapy companies [5].